Search

Patient reported outcome measures (PROMs) are associated with improved overall survival in patients with metastatic malignancy; however, routine collection of PROMs is nascent. Little is known about PROs in women with gynecologic malignancy outside of a trial setting, limiting our understanding of how routine populations experience treatment, disease and morbidity. The goal of this study was to prospectively collect and describe disease-specific PROs in a non-trial population of women with gynecologic malignancy. PROMs were assigned electronically to all patients presenting for care in our gynecologic oncology clinic. Patients received a general oncology questionnaire (EORTC QLQ C30) a disease specific questionnaire (FACT V, EORTC EN24, EORTC OV28, EORTC Cx 24), and questionnaires assessing support at home. Responses were mapped to relevant clinical variables. Descriptive statistics were performed, and comparisons made with parametric and nonparametric analyses. The association between support at home and perioperative complications was assessed via logistic regression. In the study period, 3239 unique patients were evaluated at new patient visits, post-operative visits, chemotherapy visits and surveillance visits with a PROMs completion rate of 78.1% (n = 2530 women with 4402 completions). There was no difference in completion rates based on age or self-identified race. The EORTC QLQ C-30 questionnaire was able to adequately discern differences between disease sites. Overall, scores were lower than those obtained in trial populations. PROMs responses were not associated with perioperative complications. Systematic collection of PROMs is feasible and tech-enabled workflows result in high collection rates. Quality of life scores in our clinic population were lower than published data, indicating caution should be used when extrapolating quality of life data from clinical trials to counseling and decision making around routine patient populations. • Widespread clinical collection of PROs in gynecologic oncology is feasible. • Routine clinic patients report lower PROs than patients in clinical trials. • Patients with vulvar cancer report lower quality of life than any other gynecologic malignancy. • A patient's support structure at home, as measured on PROMs, do not predict for perioperative complications. [ABSTRACT FROM AUTHOR]

• Patient reported outcomes measurements (PROMs) are an essential component of comprehensive, patient centered care. • Practical considerations and challenges to collecting PROMs in routine gynecologic oncology practice are discussed. • Pragmatic, disease-specific recommendations for the use of PROMs are provided for women with gynecologic malignancies. [ABSTRACT FROM AUTHOR]

• Patient reported outcomes measurements (PROMs) are an essential component of comprehensive, patient centered care. • Practical considerations and challenges to collecting PROMs in routine gynecologic oncology practice are discussed. • Pragmatic, disease-specific recommendations for the use of PROMs are provided for women with gynecologic malignancies. [ABSTRACT FROM AUTHOR]